Clinical reports

March 01, 2022 | Download PDF

Drug and Biologic Pipeline Q1 2023

This quarterly newsletter provides information about upcoming Food and Drug Administration (FDA) approvals. 

Drug and Biologic Pipeline Q1 2023

Drug Insights Q4-2022

IngenioRx’s DrugInsights provides a quarterly summary of Food and Drug Administration (FDA)-approved new molecular...

Drug Insights Q4-2022

Drug + Biologic Pipeline Q4 2022

We publish the IngenioRx Drug and Biologic Pipeline Update each quarter to keep you informed about upcoming FDA approvals.

Drug + Biologic Pipeline Q4 2022

IngenioRx Drug Insights Q3 2022

IngenioRx’s Q3 2022 DrugInsights provides a quarterly summary of Food and Drug Administration (FDA)-approved new...

IngenioRx Drug Insights Q3 2022

Drug + Biologic Pipeline Q3 2022

IngenioRx closely monitors drugs, biologics, and gene therapies in development. Our Q3 2022 IngenioRx Drug and Biologic Pipeline...

Drug + Biologic Pipeline Q3 2022

2021 IngenioRx Drug Trend Report*

How did we keep trend and spend down despite the effects of utilization, inflation, and new drugs introduced to the market?   

2021 IngenioRx Drug Trend Report*

Drug Insights Q2 2022

IngenioRx’s DrugInsights provides a quarterly summary of Food and Drug Administration (FDA)-approved new molecular...

Drug Insights Q2-2022*

Drug + Biologic Pipeline Q2 2022

We publish the IngenioRx Drug and Biologic Pipeline Update each quarter to keep our audiences informed about upcoming Food...

Drug + Biologic Pipeline Q2 2022

Drug Insights Q1-2022

IngenioRx’s DrugInsights provides a quarterly summary of Food and Drug Administration (FDA)-approved new molecular...

Drug Insights Q1-2022

Drug + Biologic Pipeline Q1-2022

IngenioRx Drug and Biologic Pipeline Update each quarter to keep our audiences informed about upcoming Food and Drug...

Drug + Biologic Pipeline Q1-2022

Drug Insights Q4-2021*

IngenioRx’s DrugInsights provides a quarterly summary of Food and Drug Administration (FDA)-approved new molecular entities,...

Drug Insights Q4-2021*

Drug + Biologic Pipeline Q4-2021

We publish the IngenioRx Drug and Biologic Pipeline Update each quarter to keep you informed about upcoming FDA approvals.

Drug + Biologic Pipeline Q4-2021*

*Today, we are CarelonRx, but when we created some of these documents, we were IngenioRx. This name change doesn’t impact our dedication to driving cost savings, personalizing customer experiences, and improving whole-person health.